Aprepitant: A novel antiemetic for chemotherapy-induced nausea and vomiting

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 77-85

  Massaro, Alison M ^b   Lenz, Kristi L ^a,b  

^a Merck Oncology ^*  (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aprepitant; Nausea and vomiting; Neurokinin 1; Substance P

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 INHIBITOR; DIGOXIN; DILTIAZEM; DOCETAXEL; ETOPOSIDE; HYPERICUM PERFORATUM EXTRACT; IFOSFAMIDE; IMATINIB; IRINOTECAN; KETOCONAZOLE; MIDAZOLAM; NEFAZODONE; NELFINAVIR; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PAROXETINE; PHENYTOIN; RIFAMPICIN; RITONAVIR; SEROTONIN ANTAGONIST; TOLBUTAMIDE; UNINDEXED DRUG; VINCA ALKALOID; WARFARIN;

ANGIONEUROTIC EDEMA; ASTHENIA; CLINICAL TRIAL; DATA BASE; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG USE; FATIGUE; FEBRILE NEUTROPENIA; GASTRITIS; GERIATRICS; HEADACHE; HEALTH ECONOMICS; HEARTBURN; HICCUP; HUMAN; MEDLINE; NAUSEA; NEUTROPENIA; PATIENT COUNSELING; PEDIATRICS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXICITY; TOXICOLOGY; TREATMENT CONTRAINDICATION; URTICARIA; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; MORPHOLINES; NAUSEA; PATIENT EDUCATION; VOMITING;

EID: 11144247021     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E242     Document Type: Review

References (34)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
3. Grunberg SM. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment. How are we doing? J Support Oncol 2004;2 (suppl 1):1-12.
4. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion (letter). N Engl J Med 1983; 309:796.
5. National Comprehensive Cancer Network. Clinical practice guidelines: antiemesis, version 1.2004. www.nccn.org (accessed 2004 May 15).
6. Kaizer L, Warr S, Hoskins P, Latreille J, Lofters W, Yau J, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:1050-7.
7. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, et al. A multicentre, double-blind study comparing placebo, ondansetron, and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996;7:945-52.
8. Dibble SL, Casey K, Nussey B, Israel J, Luce J. Chemotherapy-induced vomiting in women treated for breast cancer. Oncol Nurs For 2004;31:1-8.
9. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 2003;97:2880-6.
10. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end: patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
11. 3 antagonists. Br J Cancer 1997;76:1055-61.
12. Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993;72:2239-41.
13. Amin AH, Crawford TB, Gaddum JH. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. J Physiol 1954;126:596-618.
14. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074-80.
15. Product information. Emend (aprepitant). Whitehouse Station, NJ: Merck, May 2003.
16. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojaseth A, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999;340:190-5.
17. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67.
18. Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer MLA, Riviere A, et al. Prevention of cisplatin-induced acute and delayed emesis by selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer 2002;94:3032-41.
19. Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004;55: 1007-12.
20. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multi-national, randomized, double blind, placebo-controlled trial in patients receiving high-dose cisplatin: the aprepitant Protocol 052 study group. J Clin Oncol 2003;21:4112-9.
21. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Ma GJ, Eldridge K, Hippie A, et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.
22. Martin AR, Carides AD, Pearson JD, Morgan K, Elmer M, Schmidt C, et al. Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomized study of the NK-1 antagonist aprepitant. Eur J Cancer 2003;39:1395-401.
23. de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, et al. Addition of the oral NK-1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11.
24. Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LHJ, Panebianco D, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19.
25. Feuring M, Lee Y, Orlowski LH, Michiels N, De Smet M, Majumdar A, et al. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003;43:912-7.
26. Hande K, Nygren P, Fedgchin M, Vandyck K, Majumdar A, Panebianco D, et al. An open-label, balanced, two-period crossover study to investigate the influence of aprepitant on docetaxel pharmacokinetics (abstract 2094). Presented at: 2004 American Society of Clinical Oncology Annual Meeting, New Orleans, June 5-8, 2004.
27. McCrea J, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24.
28. Majumdar AK, McCrea JB, Panebianco DL, Hensey M, Dru J, Constanzer M, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150-6.
29. Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215-23.
30. 2004 Redbook. Montvale, NJ: Thompson Medical Economics, 2004.
31. Product information. Aloxi (palonosetron). Bloomington, MN: MGI Pharma, July 2003.
32. Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea/vomiting following moderately emetogenic chemotherapy: results of a double-blind, randomized, phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7.
33. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Gallagher S, et al. Palonosetron plus aprepitant and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting after emetogenic chemotherapy (abstract 8262). Presented at: 2004 American Society of Clinical Oncology Annual Meeting, New Orleans, June 5-8, 2004.
34. Warr DG, Eisenberg P, Hesketh PJ, Gralla RJ, Raftopolous H, Gabriel M, et al. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: a randomized double-blind trial in 866 patients (abstract 8007). Presented at: 2004 American Society of Clinical Oncology Annual Meeting, New Orleans, June 5-8, 2004.